Ajanta Pharma Ltd has officially denied reports suggesting it was planning to acquire a stake in Restaurant Brands Asia, the operator of Burger King in India and Indonesia. The clarification comes after market speculation linked the pharmaceutical company to Everstone Capital’s potential exit, causing volatility in Restaurant Brands Asia’s shares.
Ajanta Pharma Ltd has issued a formal statement clarifying that it has no plans to acquire Restaurant Brands Asia (RBA). Recent media reports had speculated that Ajanta Pharma or its promoters were exploring a deal to buy Everstone Capital’s stake in RBA, which operates Burger King outlets in India and Indonesia.
The company emphasized that neither its management nor its promoters are involved in any such transaction, dismissing the reports as incorrect and misleading. Following the denial, RBA’s shares fell nearly 7% from the day’s high, reflecting investor reaction to the clarification.
Key Highlights
-
Ajanta Pharma Statement: Denies any involvement in acquiring RBA.
-
Market Speculation: Reports linked Ajanta Pharma to Everstone Capital’s stake sale.
-
Share Impact: RBA shares dropped 7% after the denial.
-
Business Focus: Ajanta Pharma reiterates its commitment to core pharmaceutical operations.
-
Investor Clarity: The clarification aims to dispel rumors and stabilize market sentiment.
Ajanta Pharma’s denial underscores its focus on pharmaceuticals, distancing itself from unrelated sectors like quick-service restaurants.
Sources: Reuters, Economic Times, ScanX News